To find out effect of syp.JTV in patients suffering from cough.

Phase 2

• Conditions: Health Condition 1: null- BronchitiscoughDysnoeasore throatNasal congestion

• Registration Number: CTRI/2018/03/012516
• Lead Sponsor: Aushadhi Bhavan

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

subjects with productive cough associated with acute bronchitis, dysnoea, wheezing, chest pain, sore throat, nasal congestion

Exclusion Criteria

Subjects with Diabetes Mellitus Type I and uncontrolled Diabetes Mellitus Type II, Subjects with uncontrolled Hypothyroidism or Hyperthyroidism, Known cases of Severe/Chronic Hepatic or Renal disease, any active malignancy. Subjects giving history of significant cardiovascular event < 12 weeks prior to randomization. Subjects ECG demonstrating any signs of uncontrolled arrhythmia / acute ischemia.

Subjects X- ray chest showing any active lesion of tuberculosis and pnumonia. Subjects having severe bronchiectasis, Smokers cough, Subjects having known chronic, contagious infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
change in nature of sputum, frequency and severity of cough, breathlessness, Dysnoea, Wheezing, Chest pain, Sore throat and Nasal congestion from base line. <br/ ><br>Timepoint: 15 days

Secondary Outcome Measures

Name	Time	Method
To study Changes in spirometry parameters from base line to last visit. <br/ ><br>To study safety of Syp JTV <br/ ><br>Timepoint: 15 days